Table 2.
Response at end of induction (investigator assesseda) in patients with R/R FL and DLBCL
| n (%) | R/R FL G-atezo-polab |
R/R DLBCL R-atezo-pola |
|
|---|---|---|---|
| Pola 1.4 mg/kg (N = 3) |
Pola 1.8 mg/kg (N = 7) |
Pola 1.8 mg/kg (N = 16)c |
|
| ORR | 1 (33) | 4 (57) | 4 (25) |
| CR | 1 (33) | 1 (14) | 2 (13) |
| PR | 0 | 3 (43) | 2 (13) |
| SD | 1 (33) | 1 (14) | 1 (6) |
| PD | 1 (33) | 1 (14) | 5 (31) |
| Not evaluable | 0 | 1 (14) | 6 (38) |
Only patients who received the last dose of study drug in induction before March 1, 2018 or patients with PD or death before March 1, 2018 are included
Atezo atezolizumab, CR complete response, DoR duration of response, DLBCL diffuse large B-cell lymphoma, EOI end of induction, FL follicular lymphoma, G obinutuzumab, ORR overall response rate, PD progression of disease, pola polatuzumab vedotin, PR partial response, R rituximab, R/R relapsed refractory, SD stable disease
aAssessed by positron emission tomography-computed tomography according to modified Lugano 2014 response criteria
bTo date, a CR has been maintained from EOI in two patients receiving G-atezo-pola; DoR, 21.42 months and 2.79 months, respectively
cTo date, a CR has been maintained from EOI in two patients receiving R-atezo-pola; DoR, 10.84 months and 8.97 months, respectively